Page last updated: 2024-10-30

losartan and Neoplasms

losartan has been researched along with Neoplasms in 11 studies

Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position

Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.

Research Excerpts

ExcerptRelevanceReference
" In addition, characterization of the UGT1A locus and genetic studies directed at understanding the role of bilirubin glucuronidation and the biochemical basis of the clinical symptoms found in unconjugated hyperbilirubinemia have uncovered the structural gene polymorphisms associated with Crigler-Najjar's and Gilbert's syndrome."4.80Human UDP-glucuronosyltransferases: metabolism, expression, and disease. ( Strassburg, CP; Tukey, RH, 2000)
"Incident cancer cases were compared in patients randomized to ARBs versus controls."2.47Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. ( , 2011)
"Among the 1,281 patients with incident cancer and 5,104 controls, 333 (26."2.47Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: a nationwide case-control study. ( Chang, CH; Lai, MS; Lin, JW; Wu, LC, 2011)
"Although some tumors had vessels with greater oxygen-carrying ability than those of normal skin, most tumors had inefficient vessels."1.72Multiphoton Phosphorescence Quenching Microscopy Reveals Kinetics of Tumor Oxygenation during Antiangiogenesis and Angiotensin Signaling Inhibition. ( Bawendi, MG; Brown, EB; Chauhan, VP; Duda, DG; Fukumura, D; Han, HS; Jain, RK; Kamoun, WS; Lanning, RM; Lee, H; Martin, JD; Martin, MR; Mousa, AS; Padera, TP; Stylianopoulos, T, 2022)
"Telmisartan-treated tumours were more responsive to radiation, indicating that telmisartan reduces a therapeutically important population of transiently hypoxic tumour cells."1.56Angiotensin II type 1 receptor blocker telmisartan inhibits the development of transient hypoxia and improves tumour response to radiation. ( Benard, F; Bennewith, KL; Cederberg, RA; Colpo, N; Firmino, NS; Franks, SE; Lee, CM; Lin, KS; Pan, J; Wadsworth, BJ, 2020)
"However, cancer gene therapy has been challenged by the inherent limitation of vectors that are able to deliver therapeutic genes to tumors specifically and efficiently following systemic administration."1.42Modulation of extracellular matrix in cancer is associated with enhanced tumor cell targeting by bacteriophage vectors. ( Asavarut, P; Hajitou, A; Lee, EL; Suwan, K; Syed, N; Yata, T, 2015)
"Treatment with losartan alone did not suppress tumor growth; In contrast, treatment with doxorubicin alone decreased tumor growth; losartan and doxorubicin were administered in combination, had a synergistic effect that the tumor growth was much more inhibited."1.42Losartan improves the distribution and efficacy of doxorubicin in CT26 tumor. ( Hu, SQ; Li, XY; Liu, JX; Wang, LY; Xiao, L, 2015)

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (9.09)29.6817
2010's7 (63.64)24.3611
2020's3 (27.27)2.80

Authors

AuthorsStudies
Tukey, RH1
Strassburg, CP1
Lin, R1
Elf, S1
Shan, C1
Kang, HB1
Ji, Q1
Zhou, L1
Hitosugi, T1
Zhang, L1
Zhang, S1
Seo, JH1
Xie, J1
Tucker, M1
Gu, TL1
Sudderth, J1
Jiang, L1
Mitsche, M1
DeBerardinis, RJ1
Wu, S1
Li, Y1
Mao, H1
Chen, PR1
Wang, D1
Chen, GZ1
Hurwitz, SJ1
Lonial, S1
Arellano, ML1
Khoury, HJ1
Khuri, FR1
Lee, BH1
Lei, Q1
Brat, DJ1
Ye, K1
Boggon, TJ1
He, C1
Kang, S1
Fan, J1
Chen, J1
Martin, JD1
Lanning, RM1
Chauhan, VP1
Martin, MR1
Mousa, AS1
Kamoun, WS1
Han, HS1
Lee, H1
Stylianopoulos, T1
Bawendi, MG1
Duda, DG1
Brown, EB1
Padera, TP1
Fukumura, D1
Jain, RK1
Guo, F1
Jiao, Y1
Du, Y1
Luo, S1
Hong, W1
Fu, Q1
Li, A1
Wang, G1
Yang, G1
Wadsworth, BJ1
Cederberg, RA1
Lee, CM1
Firmino, NS1
Franks, SE1
Pan, J1
Colpo, N1
Lin, KS1
Benard, F1
Bennewith, KL1
Shen, H1
Gao, Q1
Ye, Q1
Yang, S1
Wu, Y1
Huang, Q1
Wang, X1
Sun, Z1
Yata, T1
Lee, EL1
Suwan, K1
Syed, N1
Asavarut, P1
Hajitou, A1
Scherrer-Crosbie, M1
Xiao, L1
Hu, SQ1
Wang, LY1
Liu, JX1
Li, XY1
Chang, CH1
Lin, JW1
Wu, LC1
Lai, MS1

Reviews

4 reviews available for losartan and Neoplasms

ArticleYear
Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
    Annual review of pharmacology and toxicology, 2000, Volume: 40

    Topics: Autoimmunity; Chromosome Mapping; Glucuronides; Glucuronosyltransferase; Humans; Hyperbilirubinemia;

2000
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
    Nature cell biology, 2015, Volume: 17, Issue:11

    Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms;

2015
Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals.
    Journal of hypertension, 2011, Volume: 29, Issue:4

    Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Biphenyl Compounds; Case-Contro

2011
Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: a nationwide case-control study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Aug-01, Volume: 29, Issue:22

    Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benz

2011

Other Studies

7 other studies available for losartan and Neoplasms

ArticleYear
Multiphoton Phosphorescence Quenching Microscopy Reveals Kinetics of Tumor Oxygenation during Antiangiogenesis and Angiotensin Signaling Inhibition.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 07-15, Volume: 28, Issue:14

    Topics: Angiotensins; Animals; Hypoxia; Losartan; Mice; Microscopy; Neoplasms; Oxygen; Receptors, Angiotensi

2022
Enzyme-responsive nano-drug delivery system for combined antitumor therapy.
    International journal of biological macromolecules, 2022, Nov-01, Volume: 220

    Topics: Animals; Cell Line, Tumor; Collagen; Curcumin; Drug Delivery Systems; Losartan; Matrix Metalloprotei

2022
Angiotensin II type 1 receptor blocker telmisartan inhibits the development of transient hypoxia and improves tumour response to radiation.
    Cancer letters, 2020, 11-28, Volume: 493

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cancer-Associated Fibroblasts; Cell Line, Tumor; C

2020
Peritumoral implantation of hydrogel-containing nanoparticles and losartan for enhanced nanoparticle penetration and antitumor effect.
    International journal of nanomedicine, 2018, Volume: 13

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Endocytosis; Fluo

2018
Modulation of extracellular matrix in cancer is associated with enhanced tumor cell targeting by bacteriophage vectors.
    Molecular cancer, 2015, Jun-03, Volume: 14

    Topics: Animals; Bacteriophages; Cell Death; Cell Line, Tumor; Cell Survival; Collagenases; Dependovirus; Di

2015
Losartan: A new treatment for cardiac cachexia?
    Journal of molecular and cellular cardiology, 2015, Volume: 86

    Topics: Angiotensin II; Blood Pressure; Cachexia; Humans; Losartan; Myocardium; Neoplasms

2015
Losartan improves the distribution and efficacy of doxorubicin in CT26 tumor.
    European review for medical and pharmacological sciences, 2015, Volume: 19, Issue:19

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents

2015